Jun 24, 2024 7:00am EDT Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
Jun 10, 2024 7:00am EDT Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
May 29, 2024 7:00am EDT Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
May 27, 2024 7:00am EDT Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024
May 13, 2024 7:00am EDT Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study
May 09, 2024 7:00am EDT Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study
May 06, 2024 7:00am EDT Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602
Apr 25, 2024 7:00am EDT Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
